ChiCTR-TRC-11001608 版本V1.0 版本创建时间2015/07/21 18:07:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-11001608 

最近更新日期:

Date of Last Refreshed on:

2015-05-05 11:04:01 

注册时间:

Date of Registration:

2011-01-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

冠脉搭桥手术麻醉期间应用FloTrac/Vigileo TM System比较starch HES 130/0.4与醋酸林格氏液扩容对血流动力学影响的研究

Public title:

Volume Expansion with Starch HES 130/0.4 vs. Acetated Ringer’s Solution on Haemodynamics in CABG Surgery Monitored by FloTrac/Vigileo TM System

注册题目简写:

English Acronym:

研究课题的正式科学名称:

冠脉搭桥手术麻醉期间应用FloTrac/Vigileo TM System比较starch HES 130/0.4与醋酸林格氏液扩容对血流动力学影响的研究

Scientific title:

Volume Expansion with Starch HES 130/0.4 vs. Acetated Ringer’s Solution on Haemodynamics in CABG Surgery Monitored by FloTrac/Vigileo TM System

研究课题代号(代码):

Study subject ID:

320.21

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

袁治国 

研究负责人:

袁治国 

Applicant:

Zhiguo Yuan 

Study leader:

Zhiguo Yuan 

申请注册联系人电话:

Applicant telephone:

+86 13840466665

研究负责人电话:

Study leader's
telephone:

+86 13840466665

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhiguoyuan_73zhiguoyuan@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

zhiguoyuan_73zhiguoyuan@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

沈阳中国医科大学附属第一医院麻醉科

研究负责人通讯地址:

沈阳中国医科大学附属第一医院麻醉科

Applicant address:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang

Study leader's address:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang

申请注册联系人邮政编码:

Applicant postcode:

110001

研究负责人邮政编码:

Study leader's postcode:

110001

申请人所在单位:

中国医科大学附属第一医院

Applicant's institution:

First Affiliated Hospital, China Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT-2011008

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国临床试验注册中心伦理审查委员会

Name of the ethic committee:

Ethics committee of chinese clinical tiral registry center

伦理委员会批准日期:

Date of approved by ethic committee:

2011-03-07 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学第一医院麻醉科

Primary sponsor:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University

研究实施负责(组长)单位地址:

沈阳市和平区南京北街155号

Primary sponsor's address:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University,No.155, Northern Nanjing Street, Shenyang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学第一医院麻醉科

具体地址:

沈阳市和平区南京北街155号

Institution
hospital:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University

Address:

155 North Nanjing Street, Shenyang, Liaoning, China

经费或物资来源:

中国医科大学第一医院麻醉科

Source(s) of funding:

Dept. of Anesthesiology, First Affiliated Hospital, China Medical University

研究疾病:

冠心病  

Target disease:

Coronary heart disease

研究疾病代码:

I25.101

Target disease code:

I25.101

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

在冠脉搭桥手术麻醉诱导期间应用FloTrac/Vigileo TM System比较starch HES 130/0.4与醋酸林格氏液扩容对血流动力学影响的研究  

Objectives of Study:

To compare the Volume expansion with Starch HES 130/0.4 vs. Acetated Ringer’s Solution on haemodynamics during induction in CABG Surgery monitored by FloTrac/Vigileo TM System.

药物成份或治疗方案详述:

万汶 羟乙基淀粉130/0.4 勃脉力 醋酸林格氏液 

Description for medicine or protocol of treatment in detail:

voluven hydroxyl starch HES 130/0.4 acetated ringer's solution acetated ringer's solution 

纳入标准:

冠心病心脏搭桥手术

Inclusion criteria

Selective coronary arterial bypass graft surgery.

排除标准:

1. 心脏射血分数<40%;
2. 心脏瓣膜疾病;
3. 再次手术;
4. 对 HES过敏病史;
5. 严重肝肾功能异常;
6. 困难气道.

Exclusion criteria:

1. Reduced left ventricular function (ejection fraction <40%);
2. Valvular heart disease,
3. Reoperation;
4. History of allergic reactions to HES;
5. The presence of significant liver (serum alanine aminotransferase and serum aspartate aminotransferase >2.5 times normal) or renal (serum creatinine > 1.3 mg/dL) dysfunction. 6. Patients judged under standard anaesthesia criteria to have a difficult airway.

研究实施时间:

Study execute time:

From 2011-03-07 00:00:00 To 2011-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2011-10-26 00:00:00 To 2011-10-26 00:00:00

干预措施:

Interventions:

组别:

醋酸林格氏液组

样本量:

30

Group:

Group A

Sample size:

干预措施:

静脉输注醋酸林格氏液10ml/kg扩容

干预措施代码:

Intervention:

Acetated ringer's solution 10ml/kg iv

Intervention code:

组别:

对照组

样本量:

30

Group:

Group C

Sample size:

干预措施:

持续静脉输注醋酸林格氏液2ml/kg/h

干预措施代码:

Intervention:

Acetated ringer's solution 2ml/kg/h iv drip

Intervention code:

组别:

万汶组

样本量:

30

Group:

S group

Sample size:

干预措施:

静脉输注万汶10ml/kg扩容

干预措施代码:

Intervention:

starch HES 130/0.4 10ml/kg iv

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

First affiliated Hospital, China Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

血流动力学

指标类型:

主要指标

Outcome:

hemodynamic

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝肾功能

指标类型:

次要指标

Outcome:

hepatic and renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机软件

Randomization Procedure (please state who generates the random number sequence and by what method):

computer generated

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国医科大学附属第一医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

first affiliated hospital, china medical university

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

中国医科大学附属第一医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

first affiliated hospital, china medical university

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2011-10-10 00:00:00